Integrated Quantitative Investments LLC Acquires Shares of 59,866 Puma Biotechnology, Inc. (NASDAQ:PBYI)

Integrated Quantitative Investments LLC bought a new position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 59,866 shares of the biopharmaceutical company’s stock, valued at approximately $183,000.

Other institutional investors have also made changes to their positions in the company. Gateway Wealth Partners LLC bought a new position in Puma Biotechnology during the fourth quarter worth $31,000. C2C Wealth Management LLC bought a new stake in shares of Puma Biotechnology during the 4th quarter worth about $37,000. Franklin Resources Inc. acquired a new position in Puma Biotechnology in the 3rd quarter valued at about $41,000. SG Americas Securities LLC grew its stake in Puma Biotechnology by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 11,252 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Puma Biotechnology in the 3rd quarter valued at about $68,000. 61.29% of the stock is owned by institutional investors and hedge funds.

Puma Biotechnology Stock Down 0.7 %

NASDAQ PBYI opened at $2.90 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The company has a market cap of $143.87 million, a price-to-earnings ratio of 6.04 and a beta of 1.33. The company has a 50 day moving average of $3.10 and a 200-day moving average of $2.99. Puma Biotechnology, Inc. has a 1-year low of $2.23 and a 1-year high of $6.06.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.29. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The firm had revenue of $59.10 million during the quarter, compared to the consensus estimate of $52.50 million. On average, equities research analysts expect that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on PBYI shares. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 8th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, February 28th.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.